Published in Lab Law Weekly, March 10th, 2006
Under the agreement, Acrux has a worldwide license from the Population Council to intellectual property covering the use of Nestorone with Acrux's patented metered-dose skin spray delivery technology (MDTS). Acrux will develop and commercialize Nestorone MDTS and has the right to sublicense to commercial partners.
In addition to commercial distribution of the product, Acrux (or its sublicensees) will make Nestorone MDTS available at reduced...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.